Zealand Pharma revenue and financials
kr 247.40Change from previous close: −1.47%Absolute change: −kr 3.70
In the fiscal year ended December 2025, Zealand Pharma reported revenue of kr 9.21B (+14,598.86% year over year). Net income was kr 6.46B, a net margin of 70.0%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +14,598.86%
- 2025 vs 2024
- Net margin
- 70.0%
- 2024: -1,720.9%
Financial data
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total assets | 19,762 | 15,301 | 15,949 | 16,797 | 17,180 | — |
| Current assets | 18,690 | 15,018 | 15,670 | 16,621 | 17,015 | — |
| Cash and equivalents | 4,038 | 3,849 | 4,577 | 5,973 | 7,244 | — |
| Short-term investments | 10,419 | 10,619 | 10,532 | 10,197 | 9,334 | — |
| Inventory | — | — | 0.0 | 0.0 | 10.3 | 10.7 |
| Net property, plant and equipment | 168 | 164 | 151 | 141 | 134 | — |
| Other intangible assets | 839 | — | 45.0 | — | — | — |
| Current liabilities | 1,337 | 404 | 665 | 1,179 | 1,127 | — |
| Accounts payable | 144 | 171 | 257 | 244 | 312 | — |
| Long-term debt | 312 | 307 | 303 | 298 | 294 | — |
| Total debt | 411 | 414 | 406 | 406 | 397 | — |
| Total liabilities | 1,762 | 832 | 1,118 | 1,635 | 1,571 | — |
| Total equity (incl. minority) | 18,000 | 14,469 | 14,831 | 15,163 | 15,609 | — |
| Retained earnings | 3,165 | -356 | 6.3 | 355 | 803 | — |